AbbVie Lifts Q3 Revenue and Raises Full-Year Profit Outlook
AbbVie's third-quarter revenue rose 10% on immunology and neuroscience sales, and the drugmaker raised its profit guidance and dividend by 5.2%, Dow Jones reports.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Drugmaker AbbVie reported third-quarter revenue up 10% to $17.4 billion, beating the $17.32 billion FactSet analyst estimate, according to Dow Jones Newswires. Growth was led by immunology, where sales climbed 16% to $9.17 billion on arthritis and Crohn's treatments such as Skyrizi, Rinvoq and Humira. Neuroscience revenue rose 19% to $3.39 billion.
Adjusted earnings per share came in at $3.82 against expectations of $3.73. AbbVie now expects full-year adjusted EPS of $13.95 to $13.99, up from its previous $13.76 to $13.96 range. The company also raised its quarterly dividend by 5.2% to $1.82 a share.
why it matters
The results matter for the healthcare sector and for dividend-focused investors: both quarterly results and full-year guidance came in above Wall Street expectations. Earlier acquisition-related charges weighed on reported profit, which makes the adjusted figure the more useful comparison.
market impact
Healthcare and AbbVie: results and guidance above expectations support the company's shares
- AbbVie shares pressure up — revenue and profit outlook above market expectations
tags
instruments
sources
- AbbVie 3Q Revenue Rises on Strength in Immunology, Neuroscience — Dow Jones Newswires, 30 October 2026 at 11:46 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗